Crysvita Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for xlh, orphan drug approvals, improved rare disease diagnosis, specialist center adoption, patient advocacy initiatives.

The growth in the forecast period can be attributed to growth in rare disease screening, expansion of adult xlh treatment, increased biologic orphan drug investment, broader reimbursement access, improved long term clinical outcomes. Major trends in the forecast period include rising adoption of targeted therapies for rare diseases, growth of precision medicine in genetic disorders, expansion of pediatric rare disease treatments, increased awareness of x linked hypophosphatemia, shift toward long term disease management.

The growth of personalized medicine is expected to drive the expansion of the Crysvita market in the coming years. Personalized medicine is a healthcare approach that customizes treatments and medical strategies based on individual patient characteristics, including genetic profile, environment, and lifestyle, to deliver more precise and effective outcomes. Advancements in genomic technologies and an improved understanding of disease mechanisms have enabled the development of targeted therapies aligned with specific genetic profiles. Together, these factors are accelerating the adoption of personalized medicine, enhancing treatment effectiveness and patient outcomes. Crysvita represents personalized medicine by providing a targeted therapy for X-linked hypophosphatemia (XLH), addressing the distinct genetic and metabolic requirements of individual patients to improve bone health and overall quality of life. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. These newly approved personalized therapies in 2023 also included seven cancer drugs and three treatments for other diseases and conditions. Therefore, the rise of personalized medicine is driving the growth of the Crysvita market.

Key companies operating in the Crysvita market are concentrating on the development of more patient-friendly and prefilled formulations and enhancing treatment convenience to improve therapeutic accessibility and outcomes. For example, in June 2025, Kyowa Kirin Co. Ltd., a Japan-based pharmaceutical company, received approval in Japan for a new prefilled syringe formulation of Crysvita, providing a safer and more convenient alternative to the existing vial-based version. Initially approved in 2019 and later enabled for self-injection in 2020, Crysvita is used to treat FGF23-related hypophosphatemic disorders such as XLH and tumor-induced osteomalacia (TIO). The new prefilled syringe format streamlines administration, minimizes preparation steps, and reduces the burden on patients, caregivers, and healthcare professionals. As the only therapy that directly targets FGF23, Crysvita continues to play a critical role in the management of phosphate-regulating disorders. This launch highlights Kyowa Kirin’s continued commitment to advancing patient-centric treatment solutions.

In November 2025, OMERS Life Sciences, a Canada-based life sciences-focused investment firm, acquired a 25% royalty interest in future North American sales of Crysvita from Ultragenyx for $400 million. Through this acquisition, OMERS aims to enhance portfolio returns by increasing exposure to a high-growth rare-disease therapy with an established commercial performance. The acquired royalty interest originates from Ultragenyx, a US-based biopharmaceutical company specializing in innovative therapies for serious rare and ultra-rare genetic conditions.

Major companies operating in the crysvita market are Kyowa Kirin Co. Ltd., Ultragenyx Pharmaceutical Inc.

North America was the largest region in the crysvita market in 2025. The regions covered in the crysvita market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crysvita market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the crysvita market by increasing costs associated with biologic raw materials, specialized manufacturing processes, and temperature controlled logistics. These impacts are more significant due to small patient populations and high per unit treatment costs. North america and europe experience pricing sensitivity linked to orphan drug reimbursement structures. However, tariffs are encouraging regional biologics manufacturing and public private partnerships. This supports long-term supply continuity and treatment accessibility.

The crysvita market research report is one of a series of new reports that provides crysvita market statistics, including crysvita industry global market size, regional shares, competitors with a crysvita market share, detailed crysvita market segments, market trends and opportunities, and any further data you may need to thrive in the crysvita industry. This crysvita market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Crysvita is a prescription medication indicated for the treatment of X-linked hypophosphatemia (XLH), a rare inherited condition that causes low phosphate levels in the blood, leading to weakened bones, bone pain, and other skeletal complications.

The primary strengths of Crysvita include 10 mg, 20 mg, and 30 mg. Crysvita 10 mg is a pharmaceutical formulation that typically contains cysteine as its active component, often presented as a cysteine-based supplement. These formulations are used across different patient groups, including pediatric and adult populations. The associated disease indications include X-linked hypophosphatemia and tumor-induced osteomalacia, and the medication is utilized across various settings such as hospitals, clinics, and other healthcare facilities.

The crysvita market consists of sales of injection and drug formulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.